A recent clinical trial has demonstrated that nerandomilast, an experimental anti-inflammatory drug, may offer therapeutic benefits for patients with progressive pulmonary fibrosis, a group of chronic lung disorders characterized by irreversible loss of lung function.
In the phase 3 FIBRONEER-ILD trial, sponsored by pharmaceutical company Boehringer Ingelheim, patients receiving nerandomilast exhibited a reduced rate of decline in forced vital capacity (FVC)—a key measure of lung function—over a 52-week period compared to those receiving placebo. The study enrolled individuals diagnosed with various forms of progressive pulmonary fibrosis, excluding idiopathic pulmonary fibrosis (IPF).
Forced vital capacity is the maximum amount of air a person can forcefully exhale from their lungs after taking the deepest breath possible. A slower decline in FVC is considered a positive clinical outcome, indicating that a therapy may help to preserve lung function longer.
Although more detailed results, including safety data and secondary endpoints, are yet to be published, the initial findings point to nerandomilast as a promising treatment option for this challenging group of interstitial lung diseases. The trial is registered on ClinicalTrials.gov under the identifier NCT05321082.
Nerandomilast is being investigated as a novel therapeutic agent targeting inflammation and fibrosis pathways, which are central to the progression of pulmonary fibrosis. Progressive forms of pulmonary fibrosis often lead to substantial morbidity and mortality, and current treatment options remain limited.
These findings represent a potentially important advancement in the treatment landscape for patients with non-IPF forms of pulmonary fibrosis, a population with high unmet medical need. Further studies and peer-reviewed publication of the trial data will be essential to fully understand the efficacy and safety profile of nerandomilast.
Source: https:// – Courtesy of the original publisher.
